Adaptimmune Therapeutics plc
ADAP
$0.2223
$0.00733.40%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -321.27% | -125.34% | 243.33% | -1.22% | -5.08% |
| Total Depreciation and Amortization | 0.60% | 2.77% | -3.11% | -1.43% | -0.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.91% | 136.12% | -26.03% | 60.77% | -6.77% |
| Change in Net Operating Assets | 156.11% | -66.45% | -364.08% | -63.37% | 702.28% |
| Cash from Operations | 37.18% | -214.88% | 248.35% | -117.70% | 67.50% |
| Capital Expenditure | -53.15% | 66.11% | -313.73% | 87.67% | -186.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 112.73% | -20,421.81% | -25.39% | -100.37% | 19.84% |
| Cash from Investing | 112.37% | -8,785.33% | -107.54% | -100.52% | 19.00% |
| Total Debt Issued | -100.00% | 2.04% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | -91.67% | -99.96% | 39,406.76% | -87.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 1.99% | -16.16% | 39,406.76% | -87.58% |
| Foreign Exchange rate Adjustments | -184.11% | 1,170.00% | 95.19% | -218.86% | 171.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.48% | -233.88% | 2,139.21% | -106.47% | 319.09% |
